Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304 Meeting Abstract
| Authors: | Rudin, C. M.; Mountzios, G. S.; Sun, L.; Cho, B. C.; Demirci, U.; Baka, S.; Gumus, M.; Lugini, A.; Ciuleanu, T. E.; Ahn, M. J.; Rocha, P.; Zhu, B.; Blackhall, F. H.; Yoshida, T.; Owonikoko, T. K.; Paz-Ares, L. G.; Huang, S.; Gauto, D. M.; Recondo, G.; Schuler, M. |
| Abstract Title: | Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304 |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-10 |
| Start Page: | LBA8008 |
| Language: | English |
| ACCESSION: | WOS:001511754700001 |
| DOI: | 10.1200/JCO.2025.43.17_suppl.LBA8008 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
